|28th December 2020||James V Caruso||37,037||Open or private purchase||$1.35||$49,999.95|
|28th December 2020||Jarrod Longcor||29,630||Open or private purchase||$1.35||$40,000.50|
|28th December 2020||Dov Elefant||7,407||Open or private purchase||$1.35||$9,999.45|
|16th December 2020||Stephen A Hill||7,500||Exercise of derivative||$0.00|
|5th June 2020||Dov Elefant||4,348||Open or private purchase||$1.15||$4,978.46|
|5th June 2020||James V Caruso||21,740||Open or private purchase||$1.15||$24,892.30|
|5th June 2020||Jarrod Longcor||65,218||Open or private purchase||$1.15||$74,674.61|
|4th June 2020||Stephen A Hill||18,000||Open or private purchase||$1.08||$19,438.20|
|3rd February 2020||Jarrod Longcor||40,000||Grant/award etc.||$2.71||$108,400.00|
|3rd February 2020||James V Caruso||100,000||Grant/award etc.||$2.71||$271,000.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; and CLR 125, which intends to treat micro metastatic disease.